Zibotentan Explained

Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.^[1] It is an endothelin receptor antagonist.^[2]

Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.

It failed a phase III clinical trial for prostate cancer,^[3] but other trials are planned.^[4] Tolerability of zibotentan plus docetaxel has been evaluated.^[5]

Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,^[6] bone metastasis, and heart failure.^[7]

External links

• Zibotentan

Notes and References

1. Web site: Drugs of the Future . James and Growcott . 2009 .
2. Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T . Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies . BMC Clin Pharmacol . 11 . 3 . 2011 . 21414193 . 3070638 . 10.1186/1472-6904-11-3 . free .
3. Web site: AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech. www.fiercebiotech.com. 16 April 2018.
4. Web site: Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN. GEN. 28 September 2010 . 16 April 2018.
5. Trump DL, Payne H, Miller K, etal . Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer . Prostate . 71 . 12 . 1264–75 . September 2011 . 21271613 . 10.1002/pros.21342. 29707062 .
6. Web site: A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight. adisinsight.springer.com. 16 April 2018.
7. Web site: Zibotentan - AdisInsight. adisinsight.springer.com. 16 April 2018.